Parents who have one child with an autism diagnosis can more accurately spot signs of the condition in their younger child at 12 months of age than clinicians can, according to a new study1. The advantage fades by 18 months of age, however.
The findings suggest that surveying knowledgeable parents could move up the date of autism diagnosis, enabling therapy to begin sooner.
Aviv Regev likes to work at the edge of what is possible. In 2011, the computational biologist was collaborating with molecular geneticist Joshua Levin to test a handful of methods for sequencing RNA. The scientists were aiming to push the technologies to the brink of failure and see which performed the best. They processed samples with degraded RNA or vanishingly small amounts of the molecule. Eventually, Levin pointed out that they were sequencing less RNA than appears in a single cell.
To Regev, that sounded like an opportunity. The cell is the basic unit of life and she had long been looking for ways to explore how complex networks of genes operate in individual cells, how those networks can differ and, ultimately, how diverse cell populations work together. The answers to such questions would reveal, in essence, how complex organisms such as humans are built.
Every day in the U.S., about 22 people die waiting for an organ transplant. If scientists could 3-D print organs like kidneys, livers and hearts, all those lives could be saved. For years, people have been touting personalized organ printing as the future.
But despite decades of promising work in bioengineered bladders and other kinds of human tissue, we’re not close to having more complicated organs made from scratch. Harvard professor Jennifer Lewis, a leader in advanced 3-D printing of biological tissue, has only recently developed the ability to print part of a nephron, an individual unit of a kidney.
I asked Lewis what it will take to someday print a full kidney or a similarly complex organ.
When a new drug is being tested in a controlled clinical trial, half the patients get the real drug and half get a placebo, something harmless like a sugar pill or a saline injection. But patients on the placebo often improve anyway, and that’s because they expect that they’re getting the real drug, right? Well, no. Harvard professor Ted Kaptchuk’s research has exploded that explanation. Read the full story in NeoLife.
Large genomic databases are indispensable for scientists looking for genetic variations associated with diseases. But they come with privacy risks for people who contribute their DNA. To address those concerns, a system developed by Bonnie Berger and Sean Simmons, computer scientists at MIT, masks the donor’s identity by adding a small amount of noise, or random variation, to the results it returns on a user’s query.
A new antibiotic was right under our noses—or rather, in them. Produced by a bacterium living in the human nose, the molecule kills the potentially deadly methicillin-resistant Staphylococcus aureus (MRSA) in mice and rats. When Andreas Peschel and his team stumbled upon lugdunin, they weren’t looking for a new antibiotic. They were studying S. aureus in its natural environment, the human nose. “If you want to keep the bacteria in check, you need to understand their lifestyle,” he says. “And to understand that, we also looked at its competitors.”